Clinically proven, non-invasive, and easy for patients to use at home — Elitone and Elitone URGE fill the treatment gap for mild-to-moderate urinary incontinence.
Many women avoid treatment due to invasive or time-consuming options. Elitone:
We’ve interviewed hundreds of clinicians about the challenges they see in managing mild-moderate incontinence patients. Which do you relate to?
Low Patient Follow-Through with Conservative Treatments
Pain Point: Conservative options are often prescribed, but many patients don’t adhere, leading to poor outcomes and repeat visits.
Limited Tools Between PT and Surgery
Pain Point: There’s a lack of effective, mid-tier treatment options that fit patient preferences and clinical goals.
Clinic Time Constraints
Pain Point: Clinicians want low-lift solutions that don’t add operational burden to the practice, or even generate billing opportunities with new CPT codes.
Patient Reluctance Toward Invasive Options
Pain Point: Patients want options that are non-invasive, discreet, and empowering, but are often unaware such options exist.
Insurance and Reimbursement Friction
Pain Point: Even interested clinicians may avoid recommending certain treatments due to coverage headaches.
Elitone and Elitone URGE precisely deliver pelvic floor stimulation to effectively treat the most common types of incontinence.
Over 30,000 women have used Elitone and Elitone URGE to treat incontinence. Clinical studies that supported FDA-clearance reported:
Neuromuscular stimulation has been used to improve pelvic function for decades. Elitone builds on this history by delivering well-proven waveforms through patented, easy-to-apply GelPads. Numerous clinical studies have demonstrated safety and efficacy including:
6-week study of SUI
Subjects living with stress incontinence for an average of 11 years quickly improved with Elitone. After 6 weeks of treatment 95% reported fewer leaks, with an average reduction of 71%. They also used fewer pads and had greatly improved Quality-of-Life scores. [READ]
12 Week RCT for SUI
In a large, randomized controlled study, subjects showed significant improvement over a “placebo” active sham device. This 12-week study included objective pad weight tests. Using meta data, outcomes were 66% better than typical results from vaginal stimulation devices. [MORE]
6 week study for UUI
97% of participants with urge and mixed incontinence improved with Elitone URGE after just 6 weeks. 85% of these achieved over 50% reduction in urge accidents. Quality-of-Life improved 10x more than what FDA considers “clinically significant.” [READ]
Ultrasound Visualization
The study showed visual objective evidence that Elitone contracts the pelvic muscles. This included a subject who could not achieve a Kegel contraction on her own (even though she thought she was). Elitone did the work for her. [READ]
Comparison to Alternatives
vs Internal Devices: Pelvic floor trainers coach you on how to do Kegels, but you still do the work. They don’t deliver stimulation and most are not FDA-cleared for treating incontinence. Vaginally inserted electrical stimulation devices, a different category of devices, do the work for you and are intended for treating incontinence. Unfortunately, both types use vaginal probes and require finding dedicated time and and private place for treatment. They can also be uncomfortable and include a risk of infection. Elitone is completely external, making it safe, clean and easy.
vs Electromagnetic Chairs: Chairs are expensive and cannot be used for maintenance easily. AHRQ, Effective Health Care Program No. 36 reports magnetic chairs had the worst effectiveness of non-surgical treatments.
vs Sacral Nerve Stimulation: Implants can be costly and their efficacy rate is only after passing an explant procedure. Nerve fatigue results in reduced efficacy after a few years.
vs PTNS: PTNS uses secondary nerves, not direct, which can diminish effectiveness. It typically requires weekly office visits.
Elitone is discreet, wearable, and doesn’t interrupt the patient’s day — increasing likelihood of adherence and positive outcomes.
Elitone underwent rigorous testing to obtain both Rx and OTC clearance, providing greater access for your patients. We also offer.
Patient Pay (most popular)
Most patients purchase Elitone directly from this site. Several payment options are available to spread the cost over multiple months.
HSA/FSA
Elitone is HSA/FSA eligible. To make it easy, we’ve partnered with SIKA—just choose SIKA at checkout to use your funds with no extra paperwork.
Traditional Medicare (Part B)
Elitone is covered nationwide by Medicare Part B (original or traditional) as Durable Medical Equipment (DME). It’s rented for 13 months, then owned by the patient.
A prescription with a medical necessity statement is required, and patients are responsible for any co-pays or out-of-pocket costs. Learn More.
Medicare Advantage, Medicaid, Private Payers
If a patient has Medicare Advantage (“Part C”), Medicaid, or private insurance, it is unlikely that Elitone will be covered at this time. We can provide an initial eligibility assessment. Many women opt to self-pay using their HSA/FSA funds.
Elitone complements your current care plans without adding burden to your schedule. Ideal for patients:
REQUEST MATERIALS
Provide your contact information and we’ll send materials to help you introduce Elitone in your practice.
SCHEDULE MEETING
Schedule a 15 minute video call with a product expert. It’s an easy first step in determining how Elitone can be implemented in your practice.
ASK A QUESTION
Provide your contact information and we’ll send materials to help you introduce Elitone in your practice.
